Please select the eligibility criteria that correspond to the clinical trial below.
Title: CBT Augmentation of SSRI Treatment for Geriatric GAD
Brief Summary: This study will assess whether adding cognitive behavioral therapy to the antidepressant escitalopram is effective in reducing anxiety in older adults with generalized anxiety disorder.


Options:
A: Inclusion Criteria:

* Recurrent or chronic major depressive disorder

Exclusion Criteria:

* Current diagnosis of psychotic affective disorder
* History of nonaffective psychotic disorder
* Substance dependence last three months requiring detox
* Schizotypal, antisocial, or borderline personality disorder
B: Inclusion Criteria:

* GAD diagnosis by structured interview
* Hamilton Anxiety Scale score of 18 or MORE
* Clinical Global Impressions Severity Scale score of at least 4
* Hamilton Depression Scale score of 18 or less
* Hamilton Depression Scale suicide item score less than 2
* Use of an effective form of contraception throughout the study

Exclusion Criteria:

* Hypersensitivity to venlafaxine XR
* History of seizures
* Episode of major depressive disorder in the previous 6 months
* History of any psychotic illness, bipolar disorder, or dementia
* Substance abuse and dependence during the past 6 months
* Other anxiety disorders with the exception of social phobia as long as GAD is primary
* Regular use of anxiolytics or antidepressants within 7 days of study onset
* Use of fluoxetine or monoamine oxidase inhibitors within 28 days of study onset (low dose usage of benzodiazepines will not prevent participation)
* Use of other psychotropic medication besides benzodiazepines during the study
C: Inclusion Criteria:

* Principal (i.e., most severe or pressing problem) or co-principal current diagnosis of generalized anxiety disorder
* Pretreatment score of at least 17 on Hamilton Anxiety Rating Scale

Exclusion Criteria:

* Principal diagnosis other than GAD
* Clinically judged too psychiatrically unstable to participate in the study
* Cognitive impairment or dementia
* Alcohol or other substance use disorder within 6 months prior to study entry
* Lifetime diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or bipolar disorder
* Serious, unstable, or terminal medical condition that would compromise study participation or preclude the use of escitalopram, as determined by a review of medical records
* Use of psychotropics that could not be safely tapered and discontinued for at least 2 weeks prior to study entry
* Use of depot neuroleptics within 6 weeks prior to study entry
* Unwillingness to terminate other forms of psychotherapy
* Already received adequate trial of escitalopram or CBT
D: Inclusion Criteria:

• Having received prescriptions for antidepressants in primary care for at least the past nine months

Exclusion Criteria:

* Current treatment by a psychiatrist
* Current diagnosis of substance use disorder
* Non-psychiatric indication for long-term antidepressant usage (i.e. neuropathic pain)
* Having participated in a mindfulness training (\> 3 sessions) within the last 5 years
* Inability to perform the assessments due to cognitive or language difficulties
* Younger than 18 years

Answer: C